CT-1119 

CT-1119 is an autologous human anti-Mesothelin chimeric antigen receptor macrophage (CAR-M). CT-1119 mediates CAR-dependent, antigen-dependent functional activities. CT-1119 acts as a phagocytosis inducer, tumor cell killer, pro-inflammatory cytokine inducer, and M1 macrophage polarizer. CT-1119 exhibits stronger resistance to M2 repolarization and reduces tumor burden in a mouse lung cancer xenograft model. CT-1119 can be used for the research of mesothelin-expressing solid tumors^[1].

Human

CT-1119 exhibit high CAR expression, high viability, a pro-inflammatory M1 polarization profile, and increased resistance to M2 repolarization^[1].
CT-1119 binds specifically to mesothelin, with binding activity unaffected by mesothelin shedding^[1].
CT-1119 mediates specific, CAR- and antigen-dependent phagocytosis of multiple mesothelin-expressing tumor cell lines^[1].
CT-1119 mediates robust in vitro killing of mesothelin-expressing A549 and MES-OV tumor cell lines^[1].
CT-1119, when stimulated with mesothelin, induces dose-dependent release of pro-inflammatory cytokines including TNFα in both in vitro and cell-based contexts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

10232  [NCBI]

Q13421

Mesothelin

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Anderson N, et al. 194 Pre-clinical development of CT-1119, a mesothelin targeting chimeric antigen receptor macrophage (CAR-M), for solid tumor immunotherapy[J]. 2022.